Epizyme's technology platform focuses on developing drugs to regulate a class of cancer-causing enzymes.
Mark Ahn's forced exit from the troubled Galena follows an internal investigation by the board.
Based on the positive study results, Amicus intends to seek European approval for migalastat early next year.
PDI guided lower for the third quarter and full year, but CEO Nancy Lurker, says investors should look at what's in the pipeline at the company.
AstraZeneca says the Department of Justice is ending its investigation into PLATO, a clinical trial with its heart drug Brilinta, and is not planning any further action.
Jazz Pharmaceuticals (JAZZ) shares are climbing after having coverage initiated with an 'overweight' rating and $190 price target at JPMorgan (JPM).
Apple, Amarin and Zynga are our big swing trades for today. So how should investors buy and sell?
Cellular Biomedicine Group (CBMG) CEO Wei Cao talks about the red hot life sciences sector and what's driving innovation and deals in the space.
Tekmira Pharmaceuticals (TKMR) shares are up double digits after having coverage initiated with an 'outperform' rating and $25 price target by analysts at Leerink.
Biogen Idec (BIIB) shares are climbing on Monday after the company's relapsing multiple sclerosis drug treatment, Plegridy, was approved by the FDA.
Spectrum's Beleodaq for Non-Hodgkin's lymphoma received FDA approval on July 3, but the stock then fell 26%. The same thing won't happen with Melphalan because sales numbers are already established.
Music mogul 50 Cent has taken his passion for quality sound into the high-end headphone market with his company, SMS Audio.
MannKind signed a $925 million licensing pact with French drug maker Sanofi this week to sell its diabetes drug Afrezza.
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Agilent Technologies (A) reported third quarter earnings and revenue ahead of analysts expectations.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV